The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Childhood Langerhans Cell Histiocytosis

Added text about reports from Sweden and France in which the incidence of LCH was 8.9 cases per million and 4.6 cases per million, respectively (cited Stålemark et al. as references 4 and Guyot-Goubin et al. as reference 5).

Presentation of Langerhans Cell Histiocytosis in Children

Added text to state single-site presentation in LCH also includes the thyroid, and that symptoms include massive thyroid enlargement, hypothyroidism, and respiratory symptoms (cited Burnett et al. as reference 7).

Added text to state that, although rare, LCH infiltration of the pancreas and kidneys has been reported (cited Goyal et al. as reference 10).

Diagnostic Evaluation of Childhood Langerhans Cell Histiocytosis

Added text to state that 18F-FDG PET scan abnormalities have been reported in the brains of seven LCH patients with neurologic and radiographic signs of neurodegenerative disease (cited Ribeiro et al. as reference 9).

Treatment of Childhood Langerhans Cell Histiocytosis

Added Imashuku et al. as reference 21.

Added text to state that there was a statistical difference for the 5-year survival rates between the "no etoposide" versus "etoposide" arms in the LCH-11 trial.

Added text to state that both the Japanese trial and the LCH-II trial concluded that intensified treatment increased rapid response, particularly in young children and infants younger than 2 years.

Treatment of Recurrent, Refractory, or Progressive Childhood Langerhans Cell Histiocytosis

Added Caselli et al. as reference 7.

Back to Top

< Previous Section  |  Next Section >